Drug Store News1d
FDA approves Celltrion's Xolair biosimilar
Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...
Managed Healthcare Executive3d
FDA Approves First Biosimilar of Xolair
Celltrion’s Omlyclo is interchangeable with Xolair to treat the same conditions: asthma, chronic rhinosinusitis, food allergy ...
Weekly Roundup: 15 Health Press Releases You Need to See
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and ...
Contract Pharma3d
FDA Approves Celltrion’s Biosimilar to XOLAIR
The FDA has approved Celltrion’s OMLYCLO (omalizumab-igec) as the first and only biosimilar designated as interchangeable ...
Medscape2d
Omalizumab vs Oral Immunotherapy: No Clear Winner
In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...
The Pharma Letter5d
FDA approves first interchangeable biosimilar to Xolair
On Friday, the US Food and Drug Administration (FDA) approved as the first interchangeable biosimilar to Swiss pharma giant ...
BCBS of Oklahoma requiring insured asthma patients to do their own medicine injections
Blue Cross Blue Shield of Oklahoma (BCBS), including BCBS plans in states of Illinois, New Mexico, Texas and Montana, is ...
Pharm Exec4d
FDA Approves Celltrion’s Xolair Biosimilar Omlyclo for Multiple Indications
Omlyclo, a biosimilar to Xolair, is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, immunoglobulin E-mediated food allergies, and chronic ...
Rolling Out3d
New drug outperforms therapy for severe food allergies
Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...
Morningstar4d
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
as the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps ...